Two new studies describe the benefits of the antiviral drugs nirmatrelvir-ritonavir (Paxlovid) and molnupiravir in reducing SARS-CoV-2 Omicron hospitalizations and death, with one finding that the former is more effective than the latter at lowering death rates.
A clinical trial designed to test repurposed medications for their impact on fighting COVID-19 has found no benefit to taking the antidepressant fluvoxamine (Luvox) to ease coronavirus symptoms.
Race, COVID-19 infections, and chronic disease contributed to higher COVID-related hospitalization rates for Black patients compared to white patients, according to new research from scientists at Louisiana State University (LSU) Health, New Orleans, School of Public Health published in the Journal of the National Cancer Institute.
